【作者】 马志强；

【导师】 李蔚华；

【作者基本信息】 华中科技大学 ， 内科学（专业学位）， 2022， 硕士

【摘要】 目的:该项Meta分析旨在探讨秋水仙碱对冠状动脉疾病患者的临床有效性。方法:检索中国知网、维普数据库、中国生物医学文献数据库、万方数据库、Pub Med、Embase、Cochrane Library等7个数据库,并对报告的主要心血管事件进行Meta分析。结果:共纳入8项临床随机对照研究,共12314名患者。与对照组相比,秋水仙碱可以显著降低冠状动脉疾病患者主要不良心血管事件(P<0.001;RR=0.77,95%CI0.66-0.89)、心肌梗死(P=0.004,RR=0.77,95%CI 0.64-0.92)、卒中(P=0.001;RR=0.47,95%CI 0.29-0.74)以及冠脉血运重建(P<0.001;RR=0.68,95%CI 0.56-0.83)的风险。此外,秋水仙碱安全性较高,并不会增加患者心源性(P=0.07,RR=0.70,95%CI 0.48-1.03)以及全因死亡率(P=0.44,RR=1.10,95%CI 0.86-1.41),但会显著增加胃肠道事件的风险(P=0.008;RR=1.36,95%CI 1.04-1.78)。结论:秋水仙碱可以显著降低冠状动脉疾病患者心血管事件的风险,但仍需更多的研究来确定其在心血管系统中的作用。更多还原

【Abstract】 Aim: This meta-analysis aims to explore the clinical efficacy of colchicine for patients with coronary artery disease(CAD).Methods: We searched seven databases including CNKI,VIP,CBM,Wanfang,Pub Med,Embase and Cochrane Library.Moreover,meta-analysis was performed on the major adverse cardiovascular events in all including studies.Results: Eight clinical studies with a total of 12314 patients were included.Compared with control group,colchicine could significantly reduce the risk of major adverse cardiovascular events(P < 0.001;RR = 0.77,95%CI 0.66-0.89),myocardial infarction(P = 0.004,RR = 0.77,95%CI 0.64-0.92),stroke(P =0.001;RR = 0.47,95%CI 0.29-0.74)and coronary revascularization(P < 0.001;RR = 0.68,95%CI 0.56-0.83)in patients with CAD.Moreover,colchicine showed a satisfactory safety profile with no significantly increased incidence of cardiovascular death(P = 0.07,RR = 0.70,95%CI 0.48-1.03)and all-cause death(P= 0.44,RR = 1.10,95%CI 0.86-1.41).However,the drug can significantly increase the risk of gastrointestinal events(P = 0.008,RR = 1.36,95%CI 1.04-1.78).Conclusion: Colchicine could significantly reduce the risk of cardiovascular events in patients with CAD,but much research is still needed to establish its role in the cardiovascular system.更多还原